Omar Saavedra

630 total citations
22 papers, 167 citations indexed

About

Omar Saavedra is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Omar Saavedra has authored 22 papers receiving a total of 167 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Omar Saavedra's work include Cancer Immunotherapy and Biomarkers (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Cancer Research and Treatments (3 papers). Omar Saavedra is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Cancer Research and Treatments (3 papers). Omar Saavedra collaborates with scholars based in Spain, United States and United Kingdom. Omar Saavedra's co-authors include Víctor Moreno, María Vieito, Elena Garralda, Ellen Filvaroff, Bernard Doger, Bishoy Hanna, Ida Aronchik, Juan Manuel Sepúlveda-Sánchez, Irene Braña and Zariana Nikolova and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Omar Saavedra

20 papers receiving 163 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Omar Saavedra Spain	9	86	66	36	30	16	22	167
Ruoyang Shao China	6	96 1.1×	53 0.8×	77 2.1×	29 1.0×	14 0.9×	13	206
L. Qiu China	4	75 0.9×	42 0.6×	28 0.8×	58 1.9×	12 0.8×	22	143
Devora Delman United States	6	91 1.1×	72 1.1×	44 1.2×	51 1.7×	16 1.0×	8	188
John C. Byrd United States	5	69 0.8×	43 0.7×	57 1.6×	27 0.9×	7 0.4×	10	142
Stefanie Kreutmair Germany	9	88 1.0×	49 0.7×	40 1.1×	53 1.8×	13 0.8×	21	173
Veronica Gil United Kingdom	8	108 1.3×	45 0.7×	12 0.3×	16 0.5×	29 1.8×	14	155
Louis Masclef Canada	5	138 1.6×	50 0.8×	26 0.7×	12 0.4×	37 2.3×	9	194
Anna Reischer Germany	5	24 0.3×	32 0.5×	36 1.0×	12 0.4×	21 1.3×	8	85
Paul Fordjour United States	3	115 1.3×	44 0.7×	9 0.3×	19 0.6×	10 0.6×	3	140

Countries citing papers authored by Omar Saavedra

Since Specialization

Citations

This map shows the geographic impact of Omar Saavedra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar Saavedra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar Saavedra more than expected).

Fields of papers citing papers by Omar Saavedra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar Saavedra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar Saavedra. The network helps show where Omar Saavedra may publish in the future.

Co-authorship network of co-authors of Omar Saavedra

This figure shows the co-authorship network connecting the top 25 collaborators of Omar Saavedra. A scholar is included among the top collaborators of Omar Saavedra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar Saavedra. Omar Saavedra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Hye Ryun, Juanita Lopez, Anthony B. El-Khoueiry, et al.. (2025). Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR -expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study.. Journal of Clinical Oncology. 43(16_suppl). 2609–2609.

Kim, Hye Ryun, Omar Saavedra, Andrés Cervantes, et al.. (2024). Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 2522–2522. 9 indexed citations

Stradella, Agostina, Melissa Johnson, Sanjay Goel, et al.. (2024). Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors. Cancer Medicine. 13(13). e7385–e7385. 4 indexed citations

Siu, Lillian L., Elena Garralda, Valentina Boni, et al.. (2024). Abstract CT063: Phase Ib trial of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors. Cancer Research. 84(7_Supplement). CT063–CT063. 4 indexed citations

Tolcher, Anthony W., Lillian L. Siu, Elena Garralda, et al.. (2024). Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2614–2614. 1 indexed citations

Naing, Aung, Kyriakos P. Papadopoulos, Michael J. Pishvaian, et al.. (2024). First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours. SHILAP Revista de lepidopterología. 3(1). e000249–e000249. 19 indexed citations

Kotecki, Nuria, Sylvie Rottey, Elena Garralda, et al.. (2023). Abstract CT258: A phase 1/2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors. Cancer Research. 83(8_Supplement). CT258–CT258. 1 indexed citations

Mirallas, Oriol, Omar Saavedra, María Vieito, et al.. (2023). Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients. Oral Oncology. 140. 106364–106364. 11 indexed citations

Kotecki, Nuria, Sylvie Rottey, Elena Garralda, et al.. (2023). 728 A phase 1/2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A823–A823. 1 indexed citations

10.

Saavedra, Omar, et al.. (2023). The Drying Kinetics and CFD Multidomain Model of Cocoa Bean Variety CCN51. Foods. 12(5). 1082–1082. 5 indexed citations

11.

Gelderblom, Hans, Mathilde Jalving, Ingrid M.E. Desar, et al.. (2023). Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.. Journal of Clinical Oncology. 41(16_suppl). 3012–3012. 11 indexed citations

12.

El-Khoueiry, Anthony B., Se‐Hoon Lee, Jacob Thomas, et al.. (2023). Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.. Journal of Clinical Oncology. 41(16_suppl). 2533–2533. 8 indexed citations

13.

Yap, Timothy A., Kyriakos P. Papadopoulos, Elena Garralda, et al.. (2023). A phase I/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS2669–TPS2669. 8 indexed citations

14.

El-Khoueiry, Anthony B., Juanita Lopez, Omar Saavedra, et al.. (2022). 754P A phase I/IIa dose escalation study of AFM24 in patients with epidermal growth factor receptor-expressing (EGFR) solid tumors: Results from phase I. Annals of Oncology. 33. S889–S889.

15.

Ochsenreither, Sebastian, Walter Fiedler, Marina Macchini, et al.. (2022). Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors. ESMO Open. 7(2). 100447–100447. 8 indexed citations

16.

El-Khoueiry, Anthony B., Juanita Lopez, Omar Saavedra, et al.. (2022). Abstract CT149: A phase 1/2a first-in-human study of AFM24, a CD16A/epidermal growth factor (EGFR) bispecific Innate Cell Engager (ICE®), in patients with locally advanced or metastatic EGFR-expressing solid tumors: Preliminary findings from the dose-escalation phase. Cancer Research. 82(12_Supplement). CT149–CT149. 2 indexed citations

17.

Saavedra, Omar, María Vieito, Guzmán Alonso, et al.. (2021). 1623P Phase I clinical trials (CT) forge on despite COVID-19. Annals of Oncology. 32. S1153–S1154. 1 indexed citations

18.

Moreno, Víctor, Irene Braña, Juan Manuel Sepúlveda-Sánchez, et al.. (2020). 527O CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study. Annals of Oncology. 31. S463–S464. 1 indexed citations

19.

Moreno, Víctor, Irene Braña, Juan Manuel Sepúlveda-Sánchez, et al.. (2020). 16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Annals of Oncology. 31. S5–S5. 3 indexed citations

20.

Moreno, Víctor, Juan Manuel Sepúlveda-Sánchez, María Vieito, et al.. (2020). Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma. Annals of Oncology. 31(6). 780–788. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact